Oculis Holding AG (OCS) Non Operating Interest Expenses (2022 - 2026)
Oculis Holding AG (OCS) posted quarterly Non Operating Interest Expenses of -$220921.8 for Q1 2026, up 19.58% year-over-year from -$184741.0 in Q1 2025, and up 26.73% quarter-over-quarter from -$301531.9 in Q4 2025.
Oculis Holding AG (OCS) Non Operating Interest Expenses (2022 - 2026) Analysis & Trends
Oculis Holding AG's Non Operating Interest Expenses history runs 5 years deep, the most recent figure standing at -$220921.8 for Q1 2026.
- In Q1 2026, Non Operating Interest Expenses rose 19.58% year-over-year to -$220921.8; the TTM figure through Mar 2026 stood at -$203.3 million (up 33.44% YoY), while the FY2025 annual figure was -$1.0 million, down 38.32% from the prior year.
- Non Operating Interest Expenses for Q1 2026 stood at -$220921.8, up from -$301531.9 in the prior quarter.
- The five-year high for Non Operating Interest Expenses was -$12453.7 in Q3 2023, with the low at -$304.7 million in Q3 2024.
- The 5-year median for Non Operating Interest Expenses is -$278340.9 (2025), against an average of -$32.2 million.
- The sharpest annual moves came in 2023 and 2024: Non Operating Interest Expenses jumped 99.34% in 2023, then tumbled 2446652.74% in 2024.
- Oculis Holding AG's Non Operating Interest Expenses stood at -$1.4 million in 2022, then jumped by 99.01% to -$13528.3 in 2023, then tumbled by 1984.2% to -$281955.9 in 2024, then dropped by 6.94% to -$301531.9 in 2025, then grew by 26.73% to -$220921.8 in 2026.
- Business Quant data shows OCS's Non Operating Interest Expenses at -$220921.8 in Q1 2026, -$301531.9 in Q4 2025, and -$202.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Oculis Holding AG | 879.09 Mn | 590.21 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -220,921.81 |
| Dec 31, 2025 | -301,531.92 |
| Sep 30, 2025 | -202.52 Mn |
| Jun 30, 2025 | -221,043.91 |
| Mar 31, 2025 | -274,725.88 |
| Dec 31, 2024 | -281,955.90 |
| Sep 30, 2024 | -304.71 Mn |
| Jun 30, 2024 | -96,204.03 |
| Mar 31, 2024 | -46,972.97 |
| Dec 31, 2023 | -13,528.25 |
| Sep 30, 2023 | -12,453.68 |
| Jun 30, 2023 | -18,906.98 |
| Mar 31, 2023 | -1.38 Mn |
| Dec 31, 2022 | -1.37 Mn |
| Sep 30, 2022 | -1.90 Mn |
| Jun 30, 2022 | -1.73 Mn |